ANXA8 Human
Description
ANXA8 is fused to a 20 amino acid His Tag at N-terminus and is purified by proprietary chromatographic techniques.
Product Specs
LTETLKSELS GKFERLIVAL MYPPYRYEAK ELHDAMKGLG TKEGVIIEIL ASRTKNQLRE IMKAYEEDYG SSLEEDIQAD TSGYLERILV
CLLQGSRDDV SSFVDPGLAL QDAQDLYAAG EKIRGTDEMK FITILCTRSA THLLRVFEEY EKIANKSIED SIKSETHGSL EEAMLTVVKC
TQNLHSYFAE RLYYAMKGAG TRDGTLIRNI VSRSEIDLNL IKCHFKKMYG KTLSSMIMED TSGDYKNALL SLVGSDP.
Product Science Overview
Annexin A8 (ANXA8) is a member of the annexin family, which consists of calcium-dependent membrane and phospholipid-binding proteins. These proteins are involved in various cellular processes, including membrane trafficking, inflammation, and apoptosis. Annexin A8, like other annexins, contains four annexin repeats separated by linking sequences of variable lengths .
The annexin family was first discovered in 1977 with the identification of synexin (now known as annexin A7), which caused the aggregation of chromaffin granules in the adrenal glands in the presence of free calcium . Annexin A8 shares structural similarities with other annexins, featuring a conserved core domain that binds calcium and phospholipids, and a variable N-terminal region that may confer specific functions .
Annexin A8 plays a crucial role in various cellular processes:
- Membrane Trafficking: Annexin A8 is involved in the regulation of membrane trafficking events, including endocytosis and exocytosis. It helps in the formation of vesicles and their fusion with target membranes.
- Inflammation: Annexin A8 has been implicated in the inflammatory response. It can modulate the activity of phospholipase A2, an enzyme involved in the production of pro-inflammatory mediators.
- Apoptosis: Annexin A8 is also involved in the regulation of apoptosis. It can interact with other proteins to modulate apoptotic pathways, ensuring proper cell turnover and tissue homeostasis .
Recombinant human annexin A8 is produced using recombinant DNA technology, which involves inserting the gene encoding annexin A8 into a suitable expression system, such as bacteria or mammalian cells. This allows for the large-scale production of the protein for research and therapeutic purposes.
Annexin A8, along with other annexins, has shown potential in various therapeutic applications. Studies have demonstrated positive outcomes in animal models of sepsis, myocardial infarction, and ischemia-reperfusion injury when treated with recombinant human annexins and annexin analogue peptides . These findings suggest that annexin A8 could be a valuable therapeutic agent in the treatment of inflammatory and ischemic conditions.
